NAUT
Nautilus Biotechnology Inc
NASDAQ: NAUT · HEALTHCARE · BIOTECHNOLOGY
$2.50
-3.47% today
Updated 2026-04-29
Market cap
$317.70M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.46
Dividend yield
—
52W range
$1 – $4
Volume
0.3M
Nautilus Biotechnology Inc (NAUT) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | $2.35M | $2.84M | $3.42M | $5.71M | $6.35M | $6.46M |
| Gross profit | — | — | $-2.35M | $-2.84M | $-3.42M | $-5.71M | $-6.35M | $-6.46M |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | — | $8.49M | $10.09M | $26.51M | $36.45M | $47.25M | $50.48M | $41.11M |
| SG&A | $111.68M | $1.62M | $3.31M | $21.15M | $25.95M | $28.90M | $31.00M | $25.73M |
| Operating income | $-111.68M | $-10.11M | $-15.74M | $-50.50M | $-63.62M | $-76.15M | $-81.48M | $-66.84M |
| Operating margin | — | — | — | — | — | — | — | — |
| EBITDA | $626.60M | $-9.56M | $-13.27M | $-47.47M | $-54.51M | $-74.30M | $-64.43M | $-52.54M |
| EBITDA margin | — | — | — | — | — | — | — | — |
| EBIT | $-111.68M | $-10.11M | $-15.62M | $-50.31M | $-57.92M | $-76.15M | $-70.78M | $-59.00M |
| Interest expense | $0.00 | $0.00 | $0.00 | $183000.00 | $5.82M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $626.60M | $-9.62M | $-15.62M | $-50.31M | $-57.92M | $-63.67M | $-70.78M | $-59.00M |
| Net income growth (YoY) | — | -101.5% | -62.4% | -222.1% | -15.1% | -9.9% | -11.2% | +16.6% |
| Profit margin | — | — | — | — | — | — | — | — |